Loading market dashboard
Oxford Nanopore Technologies plc
ONTTFHealthcareOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Oxford Nanopore Technologies PLC (LSE:ONT), the LSE-listed DNA sequencing company, has drawn positive reviews from RBC Capital Markets and Citi following its annual London Calling customer conference last week, with both brokers reiterating buy-equivalent ratings on the stock. RBC Capital Markets carries an outperform rating and 225p target price, while Citi rates the shares buy with a high-risk designation, noting that Oxford Nanopore trades on just 2.3 times estimated 2027 enterprise value to sales, which it considers compelling given the company's growth profile.
OXFORD, England & TOKYO--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.), one of Japan's leading genetic testing companies, today announce an international collaboration to develop and deploy advanced genomic sequencing and medicine applications based on comprehensive, nanopore sequencing in Japan. In its initial phase, the collabor.
Oxford Nanopore Technologies plc (ONTTF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
OXFORD, England & VIENNA--(BUSINESS WIRE)-- #Nanopore--ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world's first GMP-validated adventitious viral agent (AVA) detection test based on Oxford Nanopore sequencing. Designed for use in regulated biopharmaceutical quality control (QC) environments, this process is designed to ensure biologics medicines are free from viral contamination. The first-in-class solution combines.
